Notas del episodio
In this episode of Inside Pharma Leadership, I sit down with Ayla Annac, CEO and Co-Founder of InvivoSciences, to explore how precision medicine, AI, and 3D heart tissue models could help advance heart failure drug development. We discuss why traditional approaches can fall short, the importance of matching treatments to specific patient populations, and how collaboration among pharma, researchers, and investors could help bring new treatment options to patients.
Meet the GuestAyla Annac is the CEO and Co-Founder of InvivoSciences, where she works to advance precision medicine and improve…

